Closures for Pharmaceutical Preparations: A Review of Design and Test Considerations - The author examines the use of closures for products intended for injection. - BioPharm International

ADVERTISEMENT

Closures for Pharmaceutical Preparations: A Review of Design and Test Considerations
The author examines the use of closures for products intended for injection.


BioPharm International
Volume 25, Issue 12, pp. 32-36

REFERENCES

1. L. Solomun et al., J. Pharm. Biomed. Anal. 48 (3), 744–8 (2008).

2. W. Curry et al., AAPS PharmSciTech. 11 (4), 1572–9 (2010).

3. USP 32–NF 27 (Rockville, MD, 2009), pp. 4133–4140 .

4. E.J. Smith and R.J. Nash, "Elastomeric Closures for Parenterals," in Pharmaceutical Dosage Forms: Parenteral Medications, K.E. Avis, H.A. Lieberman, L. Lachman Eds. (Marcel Dekker, New York, 1st ed., 1992), pp. 445–507.

5. G.D. Chanana, X. Guo, K.E. Avis, et al., J. Parenter. Sci. Technol. 47 (1), 22–5 (1993).

6. I. Markovic, Am. Pharm. Rev. 9 (6), 20-27 (2006).

7. D.R. Jenke, PDA J. Pharm. Sci. Technol. 59 (4), 265–281 (2005)

8. FDA Container and Closure Integrity Testing in Lieu of Sterility Testing as a Component of the Stability Protocol for Sterile Products, (Rockville, MD, Feb. 2008).

9. L.S. Burrell, M.W. Carver, G.E. DeMuth, and W.J. Lambert, PDA J, Pharm. Sci. Technol. 54 (6), 449–55 (2000).

10. E. Kirsch et al., PDA J, Pharm. Sci. Technol. 51 (5), 195–202 (1997).

11. P. Kiang et al., J. Parenter. Sci. Technol. 46 (S2) (1992).


blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

Compounding Pharmacy Issues Recall, But Challenges FDA Decision
July 22, 2014
AbbVie's Acquisition of Shire Could Save $8 Billion in Taxes
July 21, 2014
AbbVie to Acquire Shire for $54.7 Billion
July 18, 2014
AstraZeneca Reveals Design for New Global R&D Center and Corporate Headquarters
July 18, 2014
Particulate Matter Prompts Baxter's Recall of IV Solutions
July 17, 2014
Author Guidelines
Source: BioPharm International,
Click here